newsfilter
← Latest News
GlobeNewswire·

Sorrento Announces Positive Phase II Results of PD-L1 Checkpoint Inhibitor IMC-001 Presented at Asian Congress of the European Society for Medical Oncology (ESMO)

IMC-001, a PD-L1 monoclonal antibody selected from Sorrento's G-MAB library, demonstrated impressive therapeutic effects in patients with heavily treated NK/T-cell lymphoma with a 60% objective response rateAchieved 100%